A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: NonSegmental Vitiligo

In brief

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Key facts

Study ID

NCT06113471

Run by

Incyte Corporation

People needed

450

Starts

2023-11-27

Expected to finish

2027-03-16

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged ≥ 18 years.
• Clinical diagnosis of nonsegmental vitiligo and meet the following:
• T-BSA ≥ 5%
• T-VASI score ≥ 4
• F-BSA ≥ 0.5%
• F-VASI score ≥ 0.5
• Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
• Willingness to avoid pregnancy or fathering children.

You may not qualify if…

• Other forms of vitiligo or skin depigmentation disorders.
• Clinically significant abnormal TSH or free T4 at screening.
• Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.
• Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.
• History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.
• Spontaneous and significant repigmentation within 6 months prior to screening.
• Women who are pregnant, considering pregnancy, or breast feeding.
• Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
• Evidence of infection with TB, HBV, HCV or HIV.
• History of failure to JAK inhibitor treatment of any inflammatory disease.
• Laboratory values outside of the protocol-defined ranges.
• Other protocol-defined Inclusion/Exclusion Criteria may apply.

Where it is running

• C2 Research Center, Llc — Montgomery, Alabama, United States
• First Oc Dermatology Research Inc — Fountain Valley, California, United States
• Center For Dermatology Clinical Research, Inc — Fremont, California, United States
• Marvel Clinical Research Llc — Huntington Beach, California, United States
• Vitiligo & Pigmentation Institute of Southern California — Los Angeles, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Clinical Trials Research Institute — Thousand Oaks, California, United States
• Skin Care Research, Llc — Boca Raton, Florida, United States
• Total Vein and Skin Llc — Boynton Beach, Florida, United States
• Driven Research Llc — Coral Gables, Florida, United States
• Florida Academic Centers Research and Education Llc — Coral Gables, Florida, United States
• Pediatric Skin Research Llc — Coral Gables, Florida, United States
• Metabolic Research Institute Inc — West Palm Beach, Florida, United States
• Dermatology and Surgery Specialists of North Atlanta — Marietta, Georgia, United States
• Advanced Medical Research Pc — Sandy Springs, Georgia, United States
• Dundee Dermatology — West Dundee, Illinois, United States
• Indiana University School of Medicine Iusm Indianapolis — Indianapolis, Indiana, United States
• Delricht Research — Baton Rouge, Louisiana, United States
• Callender Dermatology and Cosmetic Center — Glenn Dale, Maryland, United States
• Aesthetic and Dermatology Center — Rockville, Maryland, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Allcutis Research, Llc — Portsmouth, New Hampshire, United States
• Weill Cornell Medical College — New York, New York, United States
• Remington-Davis Clinical Research — Columbus, Ohio, United States
• University of Alabama At Birmingham Hospital-Whitaker Clinic — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.